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Specific Aims:  The complex nature of pain, composed of both subjective and objective 
components, makes its proper and effective management difficult for every patient.  In many 
instances factors such as race/ethnicity, which affect culture distort the objective nature of self-
reported pain levels.  Management is further compounded by opioid analgesics, which exert a 
range of adverse affects that vary in presentation and intensity between individuals.  Therefore 
research in genetics, particularly the OPRM1 gene, may expose more reliable and successful 
methods for individual pain management.  This study sought to accomplish this goal by 
evaluating the following specific aims: 1) Describe the distributions of genotypes and alleles for 
the variants, A118G and C17T, 2) Evaluate the distributions of the genotypes for A118G and 
C17T between races/ethnicities, 3) Evaluate the distribution of self-reported pain scores by 
genotype, and 4) Evaluate the distribution of opioid use by genotype. 
Methods: Eighty-three subjects were recruited from Presbyterian Hospital, University of 
Pittsburgh Medical Center.  Variables such as race/ethnicity, pain report, and opioid use were 
collected from patient report or from the medical record.  Genotypes were determined through 
DNA extraction from saliva samples.   
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Results: The proportions of C17T variant genotypes, CT and TT, were significantly higher in the 
African-American group as compared to the Caucasian group (p<.001).  The pain scores at 15 
minutes post-operatively were significantly lower in participants with either the CT and TT 
genotypes than participants having the CC genotype (p=.039).  No significant differences between
 the genotypes, A118G and C17T, were found for other categories of race/ethnicity, self-reported
pain levels, or amount of opioid use.             
 Conclusions:  The finding of higher proportions of the variant CT and TT genotypes in African-
American patients relative to Caucasian patients is consistent with the literature.  The findings of 
lower pain scores within the immediate post-operative time frame for those with CT and TT 
genotypes has not been as well documented in the literature and may support the need for further 
research in this area.  Therefore this study does not support a change in practice for pain 
management, but it does provide the basis for further research into the SNPs of OPRM1, 
particularly C17T. 
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1.0  CHAPTER 1: INTRODUCTION 
1.1 PURPOSE 
The proper management of pain has been recognized by many healthcare facilities as such a 
complex and important initiative that it is often considered the “fifth vital sign” (Lynch 2001).  
The ubiquitous nature of pain makes it a significant factor for management in many patients, yet 
despite this commonality there are stark discrepancies in both the presentation and management 
of pain.  These discrepancies vary by demographics, but recent research has indicated genetics as 
a substantial factor in the variations related to pain management.  In order to find methods to 
better manage pain, researchers are looking at the genetic influence on pain response and other 
associated outcomes.   
Determining the genotypes of opioid receptors--mu, kappa, delta, and the most recently 
discovered ORL1-- has been of particular importance as a variety of therapeutic agents act on 
these receptors (Corbett 2006). The majority of research has focused on the mu opioid 1 
receptor.  The genotype for this receptor, OPRM1, is located on chromosome 6q24-25 and at 
positions 17 and 118 it has two single nucleotide polymorphisms (SNPs).  The wild type of the 
A118G SNP is AA with AG and GG being the heterozygous and homozygous variants.  The 
wild type for the C17T SNP is CC with CT and TT being the heterozygous and homozygous 
variants (Lotsch et al 2004). 
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Researchers are finding that these variations in genotype may differ amongst 
races/ethnicities and may result in distinct differences in the perception of pain and opioid use. 
Caucasians, Hispanics, and Asians exhibit more frequent genetic variation in the A118G SNP, 
while African-Americans exhibit more frequent genetic variation in the C17T SNP (Bond et al 
1998). The phenotypic presentation of this variation in the A118G genotype has been found to 
result in increased pain and opioid use.  Evaluating outcomes associated with opioids and the 
SNP at A118G within a sample of post-cesarean women, Sia et al (2008) found increased pain 
scores amongst those with the homozygous variant genotype, GG, as compared to those with the 
homozygous wild-type genotype, AA. A substantial amount of evidence has found that variant 
genotypes of C17T are associated with higher levels of addiction.  Bond et al (1998) found that 
opioid-dependence was marginally more significant amongst those with the variant allele, T. The 
literature, however, is insubstantial in evaluating additional outcomes such pain and opioid use 
associated with the C17T SNP.  Therefore exploring the frequency of variation in A118G and 
C17T genotypes for OPRM1 amongst variables such as race/ethnicity, pain, and opioid use may 
provide support for the incorporation of genotypic evidence within a more individualized pain 
management plan. 
1.2 SPECIFIC AIMS 
The goal of this study was to explore genotypic variations in the SNPs, A118G and C17T, of the 
OPRM1 gene in order to determine its association and effect on relevant outcomes.  Identifying 
these associations was believed to lead to a better understanding of prescription of opioids and 
management of pain in the acute care orthopedic trauma population.  In order to accomplish this 
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goal the study examined the following specific aims: 
1. Describe the distributions of genotypes and alleles for A118G and C17T. 
2. Evaluate the distribution of genotypes, A118G and C17T, between races/ethnicities. 
3. Evaluate the distribution of self-reported pain score by genotype. 
 
4. Evaluate the distribution of opioid use by genotype. 
It was expected that differences in race/ethnicity, pain report, and amount of opioids 
administered would be found between each wild-type and variant SNP for A118G and C17T.  
No particular association, was qualified between these variables and the genotypes, however, it 
was predicted that these differences would offer further insight into the mechanism of pain and 
therefore allow for the advancement of individualized pain management. 
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2.0  CHAPTER 2: LITERATURE REVIEW 
2.1 HISTORICAL PERSPECTIVE OF PAIN 
Amongst the myriad of disease processes there usually exists one common component: pain.  
Historically scientists have viewed pain as both the result of emotional and physiological 
responses.  Aristotle, the 4th century BCE philosopher, proposed that pain was the result of an 
emotional response emerging from the heart (Pearl 2007). Scientists throughout the centuries, 
however, disagreed with the purely emotional component of pain and developed formal 
proposals for pain’s association with specific neurological pathways and sense organs such as the 
brain. Therefore pain has been debated as a physiological symptom with a subjective 
presentation that differs by disease process and by person.  Recently, however, brain imaging 
studies have provided the objective evidence that pain results in activation of certain cortical 
areas of the brain and matches very closely with the intensity of the subjective patient report 
(Coghill & Eisenach 2003). This finding substantiates the need to examine and treat pain as more 
of a quantifiable outcome. 
 4 
2.2 PHYSIOLOGY OF PAIN 
According to the International Association for the Study of Pain, pain is defined as: “…an 
unpleasant sensory end emotional experience associated with actual or potential tissue 
damage…” (Merskey & Bogduk 1994).  Pain is essentially a defense mechanism meant to alert 
an organism that defense barriers have been compromised and an adaptation must be made to 
prevent further tissue damage.  Therefore understanding the mechanism of pain ultimately leads 
to an improvement in management.  The systems responsible for the sensation, transduction, and 
modulation of pain are the central and peripheral nervous systems.  Although there are still some 
uncertainties about the process of pain, a general model has been accepted.  
In order for a pain response to be felt, it must first be transduced from the periphery to the 
higher order levels of functioning.  Transduction is the result of compromised tissue releasing 
chemical and mechanical stimuli that produce voltage changes in the cell. The influx of sodium 
ions into first order neuronal cells, results in an impulse traveling along the neural axon to 
presynaptic membranes where it terminates in the dorsal horn of the spinal cord. This 
termination, more specifically, depends upon the type of pain.   Sharp, well defined pain and 
dull, visceral pain, are carried along different afferent pathways.  Superficial somatic injury such 
as that resulting from an object piercing the skin is carried along fast myelinated afferent A fibers 
that terminate in the substantia gelatinosa in the II, III, and IV lamina. Deep pain, felt in result to 
injury of the ligaments, tendons, bones, organs, and other similar tissues, results in an aching, 
undifferentiated pain carried along slow unmyelinated afferent C fibers that terminate in the I 
and II lamina within the substansia gelatinosa.  
The overall result of transduction between first order neurons located in the periphery and 
second order neurons located in the spinal column is the release of chemicals from presynaptic 
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membranes that regulate the transmission of the pain signal. Excitatory neurotransmitters like 
Substance P, which binds with neurokinin-1 (NK-1) receptors, result in activation of second 
order neurons that transmit the pain signal to the brain and other higher order centers. A majority 
of these signals ascend contralaterally via the spinothalamic tract to synapse with third order 
neurons located in the thalamus. This is where a multitude of physiological factors affecting pain 
converge and result in pain discrimination.  Connections to the primary somatosensory cortex, 
result in specific physical processing of the size, location, and type of noxious stimuli whereas 
other connections with the amygdala, hypothalamus, and other regions result in the emotional, 
psychomotor, and autonomic responses to pain (Almeida et al 2004).  
Inhibitory neurotransmitters, like endorphins and enkephalins provide analgesia as they 
inhibit pain transmission to and from higher processing centers. Opioid receptor ligands, both 
endogenous and exogenous, bind receptors and produce a conformational change in the receptor 
site that activates a secondary messenger, G-protein. This activation leads to an electrolyte 
imbalance as calcium is prevented from moving into the cell and potassium moves out of the cell 
(Purves et al 2001). The ultimate result is hyperpolarization of the cell and hence a decrease in 
neurotransmitter release. The opioid receptors that produce this response are primarily located in 
the dorsal horn of the spinal column and the periaqueductal grey, PAG, matter located in the 
midbrain. Those located in dorsal horn prevent the ascending transmission of pain whereas those 
located in the PAG result in the cessation of the pain stimuli descending to the periphery (Dossey 
2004). 
Repetitive activation of this system, however, can result in complex mechanisms of 
dysregulation that sensitize some nociceptors and desensitize others resulting in an overall 
lowered threshold for pain stimulation. Nociceptors in the periphery may have a lowered pain 
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threshold after the release of inflammatory mediators such as cytokines (Carr & Goudas 1999). 
Long-term changes, however, result from neuronal remodeling of the nervous system, which is 
often attributed to the phenomenon of plasticity that allows for alternative neuronal connections. 
For example remodeling of opioid receptors after neuronal injury may increase the influx of 
calcium and therefore the transmissions of pain. Other neurotransmitter imbalances may also 
lead to results of pain dysregulation such as neuropathic pain, complex regional pain syndrome, 
and other chronic pain disorders (Nalin & Sinatra 2005). Understanding the relationship between 
the mechanisms of pain and its consequences will therefore better elucidate alternative forms of 
treatment. 
2.3  PAIN RESPONSE 
The effective relief of pain first starts with understanding its profound effects on healing.  Pain 
elicits numerous responses that may initially support the body in finding the source of the 
noxious stimuli and help to combat it.  After an extended period of exposure to these noxious 
stimuli, however, pain responses may have detrimental affects on the body.  These systemic 
effects can result in everything from hormonal dysrgulation and compromise in cardiac function 
to psychological stress, and ultimately transition into chronic pain. 
In postoperative populations experiencing acute pain, physiological responses result in 
both specific tissue injury related to the site of surgery and also a wide range systemic effects.  
Localized tissue injury activates the inflammatory response, which stimulates flooding of 
inflammatory mediators such as cytokines into the area. These mediators result in sensitized 
nociceptors that either transmit pain spontaneously or in response to a lower threshold of 
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chemical, mechanical, and other stimuli (Fabien et al 2005). The systemic effect of this 
compromise in tissue function results in increased plasma concentrations of hormones such as 
catecholamines, beta-endorphins, and cortisol. Ineffective anesthesia and analgesia management 
intraoperatively and postoperatively further enhance the neuroendocrine stress response by 
increasing fat and muscle breakdown, hyperglycemia, and decreasing immune function (Halter et 
al 1977). This effect spirals as the overproduction of catecholamines stimulates the sympathetic 
response and leads to an increased consumption of oxygen and therefore increases the work 
demands on the heart. These cardiovascular effects may present as hypertension, tachycardia, 
and increased systemic vascular resistance.  Overall the effect of pain on the heart may increase 
the possibility for myocardial ischemia. The body’s response to pain also results in a 
compromise in respiratory function. An overall decrease in pulmonary performance and hence 
oxygenation has been found with injurious processes and results in atelectasis, intrapulmonary 
shunting, and hypoxemia. The physiological effects of pain are numerous, but early and effective 
prevention and treatment of pain can minimize their extent (Berry et al American Pain Society). 
The systemic effects of pain encompass an even wider scope as they also result in 
psychological disturbances.  Beyond the stress from the physical affects of pain, many studies 
have found that a patient’s preemptive mental outlook on surgery and related processes greatly 
predict mental and behavioral outcomes postoperatively. A positive outlook can reduce pain 
intensity, compromise in physiological function, and enhance the efficacy of analgesic 
medications. In order to achieve this mental state, proper information and understanding of the 
procedure is necessary.  Egbert et al (1964) found that preoperative discussion about the surgical 
procedure, associated discomfort, and the requirements for postoperative medications 
significantly reduced discharge time. These findings suggest that patient anxiety is relieved by 
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individualized attention and therefore suggest that an personalized pain management plan that is 
understandable and properly explained to the patient, may further decrease anxiety levels (Egbert 
et al 1964).   
Physiological and psychological affects, however, are not as detrimental until they reach 
a persistent state.  Pain that last beyond the time of noxious tissue injury is defined as chronic 
pain. This development of chronic pain results in neuronal remodeling that leads to numerous 
conditions such as hyperalgesia and neuropathic pain. Hyperalgesia is in part the result of an 
increase in inflammatory cytokines such as tumor necrosis factor, TNF, that alter the flucuations 
of ion concentrations in neuronal cells. The increase of calcium into neuronal cells results in the 
increased transmission of pain signals. Neuropathic pain results in lesions forming on nerve cells 
and presents with altered perceptions of pain such as wide spread pain or sensations of burning, 
and also muscle weakness. Pain experienced with non-painful stimuli such as light touch, known 
as allodynia, is an additional consequence of neuropathic pain (Gordon et al 2005). The 
mechanism for allodynia is undefined, but it may result from a dysregulation in cytokines that 
alter the functioning of mechanoreceptors. The pathological progression to chronic pain is varied 
and extends beyond changes in the periphery as some studies have found activation of areas in 
the brain involved in the formation of memories are also associated with pain (Lenz et al 1995). 
Therefore recognizing this complexity, the prompt, effective treatment of acute pain should also 
be seen as preventing chronic pain, which is not simply a symptom but a disease process itself.  
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2.4 OPIOID MANAGEMENT  
The proper management of pain as defined by the American Pain Society concurs with the 
following guidelines: 1) prompt recognition and treatment, 2) involvement of patients in their 
pain management plan, 3) improved treatment patterns, 4) regular reassessment and adjustment 
of pain management as needed, and 5) measurement of processes and outcomes of pain 
management (Berry et al American Pain Society). These guidelines serve as an approach to 
reduce the numerous literature findings of mismanaged pain that often result from improper 
medication prescription.   
Non-prescription analgesics are the common first line treatment for pain management, as 
over half of Americans have used these “over the counter” medications. Many of these non-
opioid analgesics exert similar effects, and they are often used in combination with others or 
sometimes exclusively for their prevention of adverse effects and/or intolerance amongst certain 
populations.  Non-steroidal anti-inflammatory drugs, NSAIDs, decrease the accumulation of 
cytokines such as prostaglandins via inhibition of the cyclooxygenase enzyme. This therefore 
inhibits pain, fever, swelling and other effects of the inflammatory system. Even though, 
acetaminophen, another non-opioid analgesic, does not provide significant anti-inflammatory 
relief it is commonly used in conjunction with NSAIDs as it provides fewer side effects such as 
damage to the gastric mucosa. Although aspirin provides analgesic and antipyretic effects, it is 
commonly not used in children because of its potentially adverse outcome, Reye’s syndrome 
(Berry et al American Pain Society). 
Overall non-opioid analgesic provide mild to moderate pain relief in both acute and 
chronic populations, yet some pain related to trauma may require a stronger analgesic such as 
opioids.  In these instances it is important to understand when opioid prescription may 
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necessitate first line treatment.  Postoperative pain populations often experience severe pain 
related to critical tissue damage, organ repair, joint and bone manipulation, and many other 
procedures. Therefore prompt, effective analgesia is necessary to prevent the physical and 
psychological consequences of pain and the further development into chronic pain.   
Opioid anaglesics often provide this relief as they bind specific receptors that prevent the  
transmission of pain from the periphery to the central nervous system and also modulate the 
response from the higher function cognitive areas. These receptors are distinguished by four 
different types: mu, kappa, delta, and, the most recently discovered ORL1 (Berry et al American 
Pain Society). Martin and colleagues first formally proposed the existence of these receptors in 
the 1970s, and the first receptor, the mu opioid receptor, was discovered in nervous tissue by Pert 
and Snyder in 1973.  In the 1990s they were genotyped by Henderson and McKnight, (Pearl 
2007).  Since then research has been highly concentrated on the mu opioid receptor and more 
specifically on its subtype, mu opioid receptor 1, OPRM1, as many pharmacological agents such 
as morphine assert their affects on this receptor. This receptor (similar to the other receptors) 
functions as a G-protein that is activated by the binding of ligands such as endogenous opioids, 
beta-endorphins and enkephalins, or exogenous opioids, such as morphine and fentanyl.  
Activation results in a decreased influx of calcium and the increased efflux of potassium, which 
ultimately hyperpolarizes the cell and inhibits pain transmission via action potentials (Pearl 
2007).  
The effect of endogenous and exogenous ligands on the opioid receptors can be adjusted 
by many different factors.  One innate function of opioid receptors, especially the mu and delta 
opioid receptors, is the formation of homo- and heterodimers. This formation changes the 
pharmacologic characteristics of the receptors, as in heterodimers their expression is a 
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combination of the two receptors’ properties (Pearl 2007). Therefore, drug manipulation can 
target these homo and heterodimer formations and possibly improve therapy.   
Manipulation of the opioid receptor’s effect can also be achieved with simply adjusting 
the exogenous opioid dosages, potency, and other properties. Morphine and codeine are 
extracted from the opium poppy, Papaver somniferum, and therefore are the most pure (Freye & 
Levy 2008). In the lab, however, their dosages are adjusted for drug administration and synthetic 
derivatives, such as fentanyl, hydromorphone, and meperidine, are produced. In order to measure 
their effects, dosages, and other properties against one another, morphine is used as the standard. 
The affinity of the mu opioid receptor 1 for fentanyl is much stronger than that for morphine and 
the onset of action is also much faster, making this medication ideal for treatment in acute pain 
and intraoperative populations. Hydromorphone is commonly used as an alternative to morphine 
as it provides moderate to severe pain relief and results in the accumulation of less active 
metabolites that cause adverse effects associated with opioids such as renal failure. Meperidine 
was originally prescribed as both an analgesic and antispasmodic, yet its particularly adverse 
neurological effects of seizures and delirium hinder its prescription (Freye & Levy 2008). 
Although exogenous opioids have an essential role in pain relief, repetitive treatment can 
lead to noxious side effects, adverse reactions, increased tolerance and dependence, and 
decreased efficacy.  Side effects include constipation, dry mouth, pruritus, sedation, nausea and 
vomiting, and confusion. Adverse reactions may include respiratory depression and organ 
toxicity (Gordon & Dahl 2003).  These effects are most often controlled by careful prescription 
of appropriate dosages, combination therapy between opioids or non-opioid analgesic, and other 
alternative methods. Tolerance and dependence are two interrelated conditions, which result in 
the need for large dosages of opioids.  Tolerance most often results from opioid receptor 
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desensitization, yet the mechanism for this remains unclear (Pearl 2007). One accepted theory 
for the mu and delta opioid receptors is that they are phosphorylated by G-protein coupled 
receptor kinases (GRKs) and this results in the binding of arrestin, which prevents them from 
coupling with G-proteins. Arrestin-bound mu opioid receptors are then internalized into 
endosomes and then re-introduced to the plasma membrane with an altered level of sensitivity 
for opioid ligands. Dependence is characterized by symptoms of opioid withdrawal (Bailey & 
Connor 2005).   Some of these symptoms include restlessness, insomnia, and anxiety, and 
tachycardia.  There are no defined mechanisms for these symptoms of hyperexcitation, but some 
have found an upregulation of cyclic adenosine monophosphate (cAMP) in association with 
these symptoms. The upregulation of cAMP results in an increase in protein kinase A (PKA), 
which sets off a chain reaction of phosphorylation within the cell and ultimately leads to the 
increase in neurotransmitter release (Williams et al 2001). The increases in PKA may also 
activate GABA transporter-1 (GAT-1) that is present in the PAG and result in a cation current, 
which leads to an increased firing of action potentials (Bagley et al 2004). Understanding the 
association of these effects of tolerance and dependence in conjunction with frequent opioid use, 
an opioid naïve population was selected for this study.  
Although the mechanisms underlying morphine tolerance and dependence are still 
uncertain, finding more effective methods to prescribe opioids within each individual may 
prevent a wide range of negative effects associated with opioids.  Thus increasing the efficacy of 
opioid prescription through the use of genetic testing may counteract the side effects, adverse 
reactions, and physiological effects of both tolerance and dependence.  
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2.5 GENETIC COMPONENT 
As new developments within the field of genetics have been made, medical research seeks to 
make the connection between genotypic variations and the discrepancies seen in the presentation 
of disease and symptoms.  In particular, pain research  has found variations in the genetic coding 
for the OPRM1 gene may have significant effects on modulating pain response.  Located on 
chromosome 6q24-q25, this polymorphic receptor exhibits single nucleotide variations at the 
locations 118 and 17. At the position of 118 a single nucleotide polymorphism (SNP) converts 
the nucleotide base adenine (A) to guanine (G).  The occurrence of this transformation in one 
base it is known as a heterozygote, coding for the AG variant genotype; the occurrence of this 
transformation in two bases it is known as a homozygote, coding for the GG variant genotype.  
At position 17, this SNP results in the nucleotide base cytosine (C) being changed to thymine 
(T). The heterozygote and homozygote forms of this mutation exhibit the same pattern as the 
A118G SNP, resulting in the heterozygous and homozygous variant genotypes of CT and TT.  
The A118G SNP results in the non-synonymous amino acid change of asparagine to aspartic acid 
and C17T results in alanine being replaced by valine (Bond et al 1998). These changes ultimately 
affect the protein structure in the extracellular domain, with aspartic acid adding a negative 
charge and valine adding extra methyl groups (Matthews et al 2003). 
It is uncertain exactly how these molecular changes affect the phenotypic presentation of 
pain, but differences have been found between the wild-type and variant groups.  The SNP at 
A118G has been found to alter opioid binding.  Bond et al (1998) found the mu opioid receptor 
has an increased affinity for endogenous opioids with the genotypes that contain the variant 
allele G, but this same allele has a decreased or even no effect on the binding of exogenous 
opioids. Unlike A118G, the C17T SNP has not been shown to affect binding of opioids.  This 
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may be attributed to the similarity in the biochemical structure of the amino acid change; 
however, no studies have documented this evidence.  Both the C17T and A118G genotypes 
have, however, been evaluated for addiction, and Bond et al (1998) reported a slightly higher rate 
of addiction amongst those with the variant allele T but inconsistent results for addiction have 
been found amongst those with the variant allele G. There are also discrepancies in the literature 
findings regarding the effect of A118G and C17T SNPs on pain reports and opioid use. A meta-
analysis by Kim et al (2009) showed there is no significant difference in pain intensity between 
those individuals with the wild-type A118G genotypes versus those with the variants, yet many 
studies have found that persons those having the G allele require larger amounts of opioids. The 
findings for the C17T SNP have been limited and many have not found an association between 
this SNP and pain and/or opioid use. 
The numerous literature findings for the A118G genotype perhaps reflect the distribution 
of alleles and genotypes. The NCBI database reports the A118G variant allele G present in 
approximately 10%-17% of the population whereas the frequency of variant allele T for C17T is 
more rare and found in approximately 5%-7% of the population.  The genotypic frequencies are 
similar to allelic frequencies.  The variant genotypes for A118G, AG and GG, are found in 
approximately 10.5% to 18.8% of the population and the variants for C17T, CT and TT, are 
found in approximately 1%-10% of the population (NCBI-rs1799971 and rs1799972 1998).  
Variations in the presentation of SNPs for OPRM1 by race/ethnicity have been reported in the 
literature. The variant genotypes for the C17T SNP, CT and TT, have been found more 
frequently within African-Americans as compared to other racial/ethnic groups.  Bond et al 
(1998) found the variant allele T present in 14% of the African-American population, whereas 
Gelernter et al (1999) found the variant present in frequencies as high as 21%.  The NCBI 
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database reports the genotypes CT in frequencies between 16.7%-23% amongst African-
Americans. These findings are significantly higher than those of other races/ethnicities such as 
Caucasians who express the allele T around a frequency of 1%.  On the other hand, the G allele 
is more frequent amongst Caucasians, Hispanics, and Asian populations (LaForge et al 2000).  
According to NCBI the highest frequencies for the G allele are found in the Asian race with 
allelic frequencies as high as 49%.  The variant AG and GG genotypes are therefore also more 
frequently expressed in these populations.  The NCBI database reports the AG genotype as high 
as 58% in Asians (NCBI- rs1799971 1998).   Interestingly, however, Gelernter et al (1999) 
studied multiple ethnicities and found the G allele varied as much as 14% between African-
Americans and Ethiopians. This finding indicates the variations between not only races but also 
ethnicities and therefore supports the proper classification of participants by ethnicity for 
genotypic analyses.   
2.6 RACIAL AND CULTURAL DISCREPANCIES IN OPIOID MANAGEMENT 
Race/ethnicity is often a controversial and sometimes confounding variable within research. 
Scientific research conducted in the United States has a tumultuous history with experimental 
designs that have discriminated along the basis of race/ethnicity. Frequently research reflects the 
social ideology of the time. The most infamous example of the conflict between medical research 
and race was the design and perpetuation of the Tuskeegee experiment. Conducted for forty 
years between 1932-1972, it highlighted the discrepancies in disease and symptom management 
as researchers withheld treatment for the purpose of monitoring the the natural history of syphilis 
in the African-American male population (NPR 2002). The study’s termination followed the 
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victories for equality won during the Civil Rights Movement of the 1960s.  Further victories 
were won for the field of research as the deplorable of treatment of subjects during the 
Tuskeegee experiments led to the establishment of standards of protection for all study 
participants with creation of the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research (NIH 1979). 
 This elevation in the ethical practices of research, however, does not completely 
eliminate or simplify the inclusion or exclusion of races/ethnicities in research.  Particularly 
important to the field of genetics, race/ethnicity has been found to vary between certain 
genotypes.  For example the A118G and C17T genotypes for OPRM1 vary significantly between 
different races/ethnicities.  This variation cannot be disregarded, but it sometimes may act as a 
confounding variable based upon the study’s purpose and/or design. In the area of pain research 
race/ethnicity has been found to result in different levels of pain tolerance as well as coping 
mechanisms.  These variations may be the result of quantifiable genotypic differences, however, 
they also may result from differences in cultural practices.   
Numerous studies varying in experimental and clinical methods have been conducted in 
order to examine the difference in pain perception by race.  The most common findings for 
clinical pain have found higher levels of pain report by African-Americans versus their 
Caucasian counterparts (Edwards et al 2001). Edwards et al (2001) does admit, however, that 
these findings are not definite as pain report varies with numerous factors such as provider 
prescription of analgesics.  Experimental measures that adjust factors such as pressure and 
temperature in order to study pain tolerance and severity therefore are usually more robust in 
substantiating these differences. Most studies have found African-Americans have lowered pain 
pressure and temperature thresholds in comparison to Caucasians (Mechlin et al 2005). Mechlin 
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et al (2005) studied these findings in conjunction with blood pressure readings and found that 
African-Americans did not exhibit the documented inverse relationship between pain and blood 
pressure that Caucasians exhibited. They hypothesized that this dysregulation may result from 
differences in molecular functioning of pain regulatory mechanisms (Mechlin et al 2005). In 
examining Hispanics and Asians reactions to pain thresholds and tolerance studies have found 
mixed results.  A literature review done by Zatzick and Dimsdale (1990) found that Hispanics 
have lower pain thresholds and lower tolerance levels than Caucasians.  Additionally, Walsh et al 
(1989) noted that there were similarities between the pain reports of Hispanics and African-
Americans.  
These experimental pain studies support that molecular and genotypic differences may 
influence discrepancies in the pain report between races/ethnicities, but they often do not 
evaluate the discrepancies arising from differences in cultural coping mechanisms.  In fact 
culture is more accurately associated with ethnicity as this category includes similar customs and 
values between people of the same race.  In dealing with pain, different ethnicities utilize 
different coping mechanisms that may alter their perception of pain.  The salient use of religious 
interventions in dealing with pain intensity is most common amongst African-Americans and 
Latinos.  Jordan et al (1998) found that amongst patients with rheumatoid arthritis, African-
Americans reported a greater utilization of distraction and praying, while Caucasians reported 
higher use of controlling their perception of pain through mental manipulation. Some of these 
mechanisms have obvious benefits.   Im et al (2007) found that large support groups are essential 
to the coping mechanisms of Hispanic cancer patients, and additional research has found that 
reliance on friends and family leads to lower stress levels. Common in many cultures is the act of 
stoicism in managing pain.  Both the Bariba culture of West Africa and the Hispanic culture 
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studied in America show reluctance to exhibiting symptoms and complaints of pain (Todd 2005). 
It is therefore imperative that providers understand these differences when managing pain 
treatment and also if possible that researchers adjust for these confounding variables. 
Along with these cultural variations that influence expression, the perspective of the 
healthcare provider who determines treatment further compounds the management of pain. Many 
studies such as Cleeland et al (1994) have documented healthcare provider bias as leading to 
ethnic disparities in pain. A national study conducted by Cleeland et al (1994) found that in 
healthcare settings with a predominant minority population, such as those including Hispanics 
and African-Americans, as high as 62% of those patients were undertreated according to World 
Health Organization standards. They found compromise in treatment led to minority populations 
receiving inadequate amounts of analgesics for pain management (Cleeland et al 1994).  Often 
inadequate analgesia starts with the prescription of opioids.  Many studies have found that 
African-Americans are less likely to be prescribed opioids as compared to Caucasians for the 
same conditions.  Tamayo-Sarver et al (2003) found that African-Americans were less likely to 
receive opioids for migraines and lower back pain in comparison with both Caucasians and 
Hispanics. However, there was no significant difference in prescription of opioids between 
race/ethnicity for patients with long bone fractures (Tamayo-Sarver et al 2003).  Thus, these 
findings show that the provider’s perspective is affected by numerous factors, such as severity 
and objectivity of illness. The literature hypothesizes that these discrepancies arise from 
prejudice on the behalf of the provider, miscommunication, and/or lack of trust between the 
provider and patient.  Researchers are, however, finding that racial/ethnic affiliation may have 
stronger, more physiological connection than purely subjective opinions.  Examining cortical 
areas that are activated in pain processing, the anterior cingulated cortex (ACC), Xu et al (2009) 
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found that people were more likely to show increases in ACC activity and hence empathy when 
they viewed painful stimuli applied to members of their own race/ethnicity. Interestingly, 
however, conscience opinions for others’ pain ratings did not show a significant difference in 
judgment between those of similar or dissimilar race/ethnicity (Xu et al 2009). This suggests that 
providers’ response to patients is both a combination of subjective opinions and objective, 
subconscious cortical processing.   
The association and between race/ethnicity and genetic research is dynamic.  Factors of 
race/ethnicity such as culture and even provider bias may confound the finding of a strictly 
genetic basis for outcomes like pain and opioid use.  The evidence for differences in pain 
tolerance between races/ethnicities and the findings for OPRM1 suggest that there may be an 
underlying molecular or genetic component responsible for these discrepancies.  The advances in 
genetic research may equalize medical treatment between all races/ethnicities as more objective 
findings support subjective patient reports.  It is therefore necessary to include a diverse range of 
races/ethnicities in order to evaluate genotypic differences; however, experimental designs 
should include measures to limit the confounding results.   
2.7  SUMMARY 
This review shows both the subjective and objective nature of pain.  Often a person’s self 
reported pain response may vary with their race/ethnicity as this characteristic has an essential 
role in shaping culture and hence personality.  Scientists, however, seek to quantify this 
subjectivity in order to appropriately and effectively treat pain.  In understanding the 
mechanisms of pain and its detrimental effects such as the progression to chronic pain one can 
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develop treatments that reduce adverse outcomes.  The implication for genetic research is 
therefore to better customize pain management for each individual patient.  The OPRM1 gene is 
of particular interest because in binding both endogenous and exogenous opioids, it exerts a 
direct effect on pain modulation.  The research has already shown those with the variant allele, 
G, have an altered response to endogenous and perhaps exogenous opioids.  Therefore research 
into the SNPs at locations A118G and C17T may provide insight into how the receptor or ligand 
may be manipulated for pharmaceutical purposes.  This study seeks to explore the genotypic 
frequencies of these two SNPs, A118G and C17T, in conjunction with outcomes such as pain 
levels, opioid use, and the related variable of race/ethnicity in order to provide support for the 
implementation of genetic testing within pain management. 
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3.0  CHAPTER 3: METHODS 
 
3.1 DESIGN 
This study was performed as a secondary analysis of a study designed as a prospective, 
comparative study that examined the variations in genotype for the mu opioid receptor, OPRM1 
(The association between mu-receptor genotypes and postoperative pain response, American 
Association of Nurse Anesthetists Foundation, Dr. Richard Henker). These variations in 
genotype were examined for associations between the race/ethnicity of the subject, use of 
opioids, and pain response in isolated extremity orthopedic trauma patients.  
All of the data for the parent study was collected by investigators with clinical privileges 
at Presbyterian Hospital-University of Pittsburgh Medical Center.  Data collected for analysis 
included race/ethnicity, preoperative pain scores, post-anesthesia care unit (PACU) pain scores 
within the first 15 and 45 minutes in the PACU. Amount of opioid used was measured during the 
time in the operating room and the first 45 minutes in the PACU.  Race/ethnicity was collected 
from patient report or the medical record.  The pain response was measured using an 11-point 
verbal pain score, VPS. The type, amount of opioid as well as the time the opioid was given were 
obtained from the perioperative and PACU record.  Saliva samples were also collected in the 
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post-PACU setting.  The DNA for genotypic analyses was extracted from saliva preserved in 
Oragene DNA self collection kit from DNA Genotek corporation (Ottawa, ON, Canada).  
 
3.2 SAMPLE 
The inclusion criteria included the following: having single isolated extremity fracture and being 
between the ages of 18-70 years.  Exclusion criteria included: receiving opioids within the past 6 
months (not including the hospital admission for current injury), having a history of alcohol 
abuse, using alcohol within the last 24 hours (3 drinks or greater), having a history of mental 
illness, currently using phenothiazines, having a history of hepatic disease, having a history of 
renal disease, having an American Society of Anesthesiologist Physical Status rating greater than 
3, and having a history of neurological trauma.   
The decision to conduct the parent study in a relatively opioid naïve orthopedic trauma 
population (experienced opioid use on the current admission for isolated extremity orthopedic 
surgery) was done specifically to limit the effects of opioid tolerance that may affect opioid use 
subsequent to variations in the opioid receptors.  The populations with isolated extremity 
fractures included subjects from a wide age span who were also usually younger and therefore 
less susceptible to co-morbidities that may distort opioid response.  This population of 
orthopedic trauma also usually has a significant amount of pain and hence opioid use, which 
provides a substantial amount of data for analysis.    
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3.3 DATA COLLECTION 
3.3.1 Recruitment 
Recruitment for the parent study was conducted in the preoperative holding area and medical 
surgical units at Presbyterian Hospital-University of Pittsburgh Medical Center.  After reviewing 
demographics, co-morbidities, physical status, laboratory values, preoperative medication use, 
and intraoperative, data from the chart and patient report, patients were enrolled who met the 
selection criteria and provided informed consent. 
3.3.2 Anesthesia Management 
Standard intraoperative anesthesia management included: Midazolam <4 mg; Propofol  
(<3mg/kg) or Sodium thiopental 4-6mg/kg; Succinylcholine or Rocuronium; Fentanyl; 
hydromorphone; vasoactive medications as needed; and inhaled agents such as isoflurane, 
sevoflurane, or desflurane.  No greater than 400mcg of phenylephrine and no greater than 25mg 
of ephedrine were used during surgery. 
3.3.3 Pain Scale 
The verbal pain response scale was implemented preoperatively and at 15 and 45 minutes in the 
PACU. The 11-point VPS was explained to patients prior to surgery, where a rating of 0 is 
absence of pain and 10 is the worst pain imaginable (Au et al 1994). 
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3.3.4 Opioids 
The type, amount, and time of administration for opioids given were recorded from the 
perioperative, PACU, and post-PACU data.  The amount of fentanyl administered was recorded 
and included with the opioid medications and also recorded in a separate category.  Fentanyl was 
coded as total amount and as mcg/kg.  In order to standardize the amount of opioid used, it was 
converted to mg of morphine and divided by kilograms of body weight.   
3.3.5 Demographic Data 
Gender, race/ethnicity, age, weight, height, body mass index, and mechanism of injury were 
obtained from the medical record and patient report.  Race/ethnicity was recorded with the 
following NIH categories: Caucasian, Black or African-American, Asian or Pacific Islander, 
Hispanic, and Native American (NIH 2001). Co-morbidities, such as diabetes mellitus, 
hypertension, cardiac heart failure, myocardial infarction, and chronic obstructive pulmonary 
disease, past surgical history, smoking, and alcohol use were extracted from the medical record 
and also patient report.  The physical status was assessed using the following American Society 
of Anesthesiologist scale, where 1 – a normal healthy patient,  2 – a patient with mild systemic 
disease and no functional limitations, 3 – a patient with moderate to severe systemic disease that 
results in some functional limitation, 4 – a patient with severe systemic disease that is a constant 
threat to life and functionally incapacitating, 5 – a moribund patient that is not expected to 
survive 24 hours with or without surgery, and 6 – a brain dead patient whose organs are being 
harvested.  If the procedure was an emergency, the physical status rating was followed by “E”. 
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3.3.6 Saliva Samples 
Saliva samples for the parent study were collected with the use of the Oragene DNA self-
collection kit.  This collection kit contains a vial for saliva collection where upon closing of the 
vial the saliva mixes with a stabilization buffer.  This saliva/buffer combination is stable at room 
temperature for prolonged periods of time.  The DNA was then extracted by Dr. Yvette Conley’s 
lab using the protocol and reagents supplied by the Orangene kit.  This extraction process usually 
yields 100ug of DNA from one saliva sample.  This quantity of DNA was more than required for 
genotypic analyses for this proposed project. 
3.4 DATA MANAGEMENT 
 
3.4.1 Genotype Data 
The two variants of the mu opioid receptor gene that were genotyped and analyzed for this study 
are the A118G (rs1799971) and C17T (rs1799972).  At the position 118 the AA is the 
homozygous wild type whereas the AG and GG are the genetic variants.  At the position 17 the 
CC homozygous wild type while the CT and TT are the variant SNPs.  The determination of 
these genotypes was accomplished with a sequencing reaction that was facilitated by the fact that 
only one sequencing reaction was needed due to A118G and C17T being within 101 base pairs 
of each other in exon 1.  In order to identify the variants, primers were designed to flank the 
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variants and that were then amplified with polymerase chain reaction (PCR).  These amplified 
PCR fragments were then cleaned using exoSAP reagents (US Biochemicals, Cleveland, OH) 
and sequenced using Big Dye Cycle Sequencing reagents (Applied Biosystems Inc, Foster City, 
CA).  In order to isolate the desired variants, the products were electrophoresed using an 
AB1377 automated sequencer (Applied Biosystems, Inc).  These data were then converted to 
viewable data and assigned genotypes using Sequencer software (Gene Codes Corporation, Ann 
Arbor, MI).  All of the genotype data were stored in a secure data file within SPSS (SPSS 17.0, 
Chicago, IL) on a password protected computer. 
3.4.2 Data Cleaning 
All data were entered into SPSS for organization and analyses.   Retrospective data were also 
collected for some variables such as opioid use as the data were not available for during 
prospective collection.  All categorical data were assigned a number code.  Spot checks were 
performed frequently throughout the data entry period to verify data were entered correctly into 
SPSS from the patient records. 
3.5 ANALYSIS 
3.5.1 Preliminary Analysis 
Using exploratory data analysis, the data were initially screened to identify any data anomalies 
that may invalidate the planned parametric analysis. Age, fracture type, opioid use, and pain 
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scores were evaluated using exploratory analyses.   Descriptive statistics were computed 
including frequency counts and percentages, measures of central tendency (means, medians, 
modes) and measures of dispersion [standard deviations (SD), interquartile ranges (IQR), 
minimums (Min), maximums (Max)]. Descriptive and exploratory data analyses were performed 
for the total sample and within categories of the genotypes (A118G, C17T) and race/ethnicity.  
The variables of interest for this study were the variant genotypes of the opioid mu receptor 
(OPRM1), A118G (rs1799971) and C17T (rs1799972), and also race/ethnicity, which was 
considered a related variable to both the OPRM1 genotypes and the outcome variables of pain 
and opioid use. The level of statistical significance for two-sided hypothesis testing was set .05, 
and 95% confidence intervals (CI) where computed for point estimates.  In order to evaluate the 
consistency of the genotypes, Hardy-Weinberg Equilibrium (HWE) analysis was performed. The 
A118G sample was found to be within HWE (X2=1.54; df=1; p=.215).  The C17T sample, 
however, was not found to be within HWE (X2=5.43; df=1; p=.020).  This therefore indicated 
that significant results for C17T sample would not be relevant to the C17T population.   
3.5.2 Primary Analysis 
The preliminary analysis of genotypic frequencies for C17T and A118G, revealed one 
subject for each of the homozygous variants, TT and GG.  Realizing that the literature reports 
more significant differences between the wild-type and variant genotypes than between the 
variants themselves, the homozygous and heterozygous variants for A118G and C17T were 
collapsed (AG/GG and CT/TT).   The decision to collapse the genotypes resulted in higher cell 
counts and therefore a more robust statistical analysis.  It was also felt some races/ethnicities 
should be excluded or collapsed for racial/ethnic analyses as initial analyses revealed low cell 
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counts.  Cross-tabulations analysis for all races/ethnicities (analyzed with the collapsed variant 
genotype categories) revealed that 75-83% of cell counts were below the minimum expected cell 
size of 5 for a valid analysis. The American Indian and Asian categories were dropped from 
analyses as they only had one subject each with genotypic data.  There also were three subjects 
who had claimed race unknown and so they were excluded from the racial/ethnic analyses.  
Lastly, there were four subjects with genotypic data for the Hispanic race/ethnicity, yet noticing 
their inclusion still resulted in 67% of cell counts being below the minimum expected count of 5 
and that they had indicated Hispanic and Caucasian during the screening process their genotypic 
data were collapsed with the Caucasian race/ethnicity.  This process of excluding and collapsing 
racial/ethnic categories resulted in analysis being performed for two racial/ethnic categories, 
Caucasian and African-American, and only 25% (1 cell) of the cell counts were below the 
expected count.  Understanding, however, that cell counts for some categories were still sparse 
(as many as 75% below 10) it was decided to use the Fisher exact test, instead of the Pearson 
Chi-Square test of independence, to investigate distributional differences in race/ethnicity 
between genotypic categories.  
The continuous dependent variables, pain score and opioid use, were evaluated for 
normality of distribution in order to determine if parametric or non-parametric tests should be 
used. To assess for normality, the Kolmogorov-Smirnov test was evaluated for group sample 
sizes above 50 and the Shapiro-Wilk test was evaluated for group samples sizes under 50.  A p-
value below the significance level of .05 for the Kolmogorov-Smirnov or Shapiro-Wilk tests or 
either group indicated that the distribution was not normally distributed and therefore were 
evaluated with non-parametric significance testing. The A118G distribution for pain scores for 
both AA (p=.162) and AG/GG (p=.447) genotypes showed that only the preoperative pain scores 
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were approximately normally distributed and therefore tested with both the two sample t-test 
(parametric) and Mann-Whitney U-test (non-parametric).  The PACU pain scores at 15 minutes 
for both AA (p<.001) and AG (p=.016) genotypes and at 45 minutes for AA (p=.038) and 
AG/GG (p=.026) genotypes were not normally distributed and therefore evaluated with only the 
Mann-Whitney U-test.  Similar to A118G, the distribution of pain scores for C17T showed that 
the preoperative scores for both CC (p=.200) and CT/TT (p=.258) genotypes were normally 
distributed and therefore evaluated with the two sample t-test and with the Mann-Whitney U-test.  
The opioid use for A118G showed that the data for the wild-type, AA, were not normally 
distributed for OR opioid use (p=.004), OR opioid use by weight (p=.042), PACU opioid use 
within the first 45 minutes (p<.001), and also PACU opioid use within the first 45 minutes by 
weight (p<.001).  The opioid use for AG/GG, however, was normally distributed for OR opioid 
use (p=.436), PACU opioid use within the first 45 minutes (p=.167), and also PACU opioid use 
within the first 45 minutes distributed by weight (p=.135), but not for OR opioid use by weight 
(p=.008).   Despite the findings of normal distributions for AG/GG, only the Mann-Whitney U-
test was performed as the two genotype groups, AA and AG/GG, were being compared against 
each other.  The opioid use for the CC genotype was not normally distributed amongst any of the 
categories, OR opioid use (p<.001), OR opioid use by weight (p<.001), PACU opioid use with 
the first 45 minutes (p=<.001), and PACU opioid use within the first 45 minutes by weight 
(p<.001).  The CT/TT genotypes were normally distributed for each category, OR opioid use 
(p=.912), OR opioid use by weight (p=.559), PACU opioid use with the first 45 minutes 
(p=.410), and PACU opioid use within the first 45 minutes by weight (p=.938).  Therefore 
because the opioid amounts for CC genotype were not normally distributed, C17T genotypes 
were compared with the Mann-Whitney U-test. 
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4.0  CHAPTER 4: RESULTS 
 
4.1 CHARACTERISTICS OF SUBJECTS 
Characteristics of subjects are reported in Table 1. The sample consisted of 83 subjects, 18-70 
years of age (M=38.6; SD=13.04) with mostly lower extremity fractures (ankle/tibia/fibula) (See 
Table 2). The racial/ethnic makeup of the sample consisted of 64 Caucasians, 10 African-
Americans, 4 Hispanics, 1 Native American, 1 Asian, and 3 of unknown race/ethnicity. The 
mean operating room (OR) opioid use for all subjects was 34.563 (SD=19.378).  The mean by 
weight distribution was 0.414 (SD=0.248).  The mean post-anesthesia care unit (PACU) opioid 
use after 45 minutes was 6.745 (SD=5.981) and by weight distribution the mean was 0.085 
(SD=0.076). The mean preoperative pain score was 4.64 (SD=3.02).  The mean PACU pain 
score at 15 minutes was 6.53 (SD=3.45).  The mean PACU pain score at 45 minutes was 6.50 
(SD=2.90).  
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Table 1. Descriptive Statistics for the Characteristics of Subjects 
 
Characteristics n        Mean   Min-Max          SD   Median IQR 
Age (years) 82 38.60 18-70 13.04 38.00 18.00 
OR opioids  80 34.989 5-108 19.277 33.000 19.580 
OR opioids/weight 80 0.414 0-1.460 0.248 0.360 0.261 
PACU opioids 80 6.745      0-26.660 5.981 6.300 10.000 
PACU opioids/weight 80 0.085 0-0.275 0.076 0.085 0.135 
Preoperative Pain Score 77 4.64 0-10 3.02 5.00 5.00 
PACU Pain Score at 15 min 82 6.53 0-10 3.45 6.70 5.0 
PACU Pain Score at 45 min 81 6.50 0-10 2.90 7.00 4.00 
 *SD=Standard deviation, IQR=Interquartile range 
 
Table 2. Fracture Type 
 
Fracture Type n % 
Ankle  26 31.3 
Femur 10 12.0 
Tibial plateau 16 19.3 
Tib Fib 25 30.1 
Acetabular 1 1.2 
Humerus 1 1.2 
Radial 1 1.2 
Hip 1 1.2 
Ulnar 1 1.2 
Total 83 100 
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4.2 DISTRIBUTION OF A118G AND C17T GENOTYPES AND ALLELES 
The first specific aim was to examine the distributions of genotypes and alleles within the total 
sample.  The distributions of A118G and C17T genotypes for the entire sample are reported in 
Figure 1.  The distribution of A118G and C17T alleles for the entire sample are reported in 
Figure 2.  For A118G, the variant allele had a frequency of about 12.65% (95% CI= 7.59, 17.71). 
For C17T, the variant allele had a frequency of 4.2% (95% CI= 1.66, 7.28). The genotypic 
distribution for A118G was as follows: 75.9% (n=63) for AA (95% CI= 66.7, 75.9), 22.9% 
(n=19) for AG (95% CI= 13.85, 31.93), and 1.2% (n=1) for GG (95% CI= -1.14, 3.54).  The 
genotypic distribution for C17T was as follows: 92.8% (n=77) for CC (95% CI= 87.20, 98.34), 
6.0% (n=5) for CT (95% CI= 0.90, 11.14), and 1.2% (n=1) for TT (95% CI= -1.14, 3.54).   
 
Figure 1. Distributions of A118G and C17T Genotypes in the Total Sample  
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Figure 2. Distributions of A118G & C17T Alleles in the Total Sample  
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4.3 DISTRIBUTIONS OF A118G AND C17T GENOTYPES AND ALLELES BY 
RACE/ETHNICITY 
The second specific aim was to examine the distributions of the genotypes and alleles by 
race/ethnicity. The frequencies and percentages of genotypes and alleles by race are reported in 
Tables 3 and 4.  Contingency table analyses using Fisher exact test showed no differences in the 
racial/ethnic distribution between A118G categories [OR=1.22; 95% CI= (0.23, 6.40); p=1.00]. 
For C17T, however, African-Americans had a greater odds of having the CT or TT genotypes 
relative to Caucasians [OR=63.00; 95% CI= (6.12, 648.94); p<.001]. 
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Table 3. Distributions of A118G Genotypes and Alleles by Race/Ethnicity 
 
Table 4. Distribution of C17T Genotypes and Alleles by Race/Ethnicity 
 
 Genotype [% (n)] Alleles [% (n)] 
   Wild Type Polymorphism 
Race/ethnicity AA  AG GG A G 
Caucasian 76.6 (n=49) 21.9 (n=14) 1.6  (n=1) 87.5(n=112) 12.5 (n=16) 
African-American 80.0 (n=8) 20.0 (n=2)  0 (n=0) 90 (n=18) 10 (n=2) 
Total 77.0 (n=57) 21.6 (n=16) 1.35 (n=1) 87.8(n=130) 12.2 (n=18) 
 
 Genotype [% (n)] Alleles [% (n)] 
 Wild Type Polymorphism 
Race/ethnicity CC CT TT C T 
Caucasian 98.4 (n=63) 1.6 (n=1) 0 (n=0) 99.2 (n=137) 0.8 (n=1) 
African-American 50.0 (n=5) 40.0 (n=4) 10.0 (n=1) 70  (n=14) 30 (n=6) 
Total 91.9 (n=68) 6.76 (n=5) 1.35 (n=1) 95.3 (n=141) 4.7 (n=7) 
 
 
 
4.4 DISTRIBUTION OF PAIN SCORES BY A118G AND C17T GENOTYPES  
The third specific aim was to examine the differences in the distribution of pain scores by 
genotype.  Table 5 summarizes the pain scores by genotype.  There was no significant difference 
in levels of self-reported levels of pain found between the wild-type and variant genotypes for 
A118G.  For C17T, however, a significant difference between the CC and CT/TT genotypes was 
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found for PACU pain within the first 15 minutes (p=.039).  The subjects with CT/TT genotypes 
were found to have a lower median and mean values for pain reported within the first 15 minutes 
in the PACU in comparison to those subjects with the wild-type, CC, genotype. 
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Table 5.  Descriptive and Comparative Statistics for Pain Scores by A118G and C17T 
Genotypes 
Genotypes/Outcomes Mean 
 
Median  Min-Max SD  IQR Test Stat 
t-test & Mann-Whitney U-test  
AA 
Preoperative Pain 
PACU Pain 15 
PACU Pain 45 
 
4.78 
6.81 
6.40 
 
5.00 
8.00 
7.00 
 
0.00-10.00 
0.00-10.00 
0.00-10.00 
 
3.12 
3.38 
3.00 
 
5.00 
5.20 
4.00 
 
[(t=.793; p=.430)(U=494.00; p=.441)] 
(U=498.00; p=.185) 
(U=540.00; p=.587) 
 
 
AG/GG 
Preoperative Pain 
PACU Pain 15 
PACU Pain 45 
 
4.21 
5.68 
6.84 
 
4.00 
7.00 
8.00 
 
0.00-9.00 
0.00-10.00 
2.00-10.00 
 
2.70 
3.64 
2.63 
 
4.00 
7.00 
4.00 
CC 
Preoperative Pain 
PACU Pain 15 
PACU Pain 45 
 
4.52 
6.85 
6.44 
 
5.00 
8.00 
7.00 
 
0.00-10.00 
0.00-10.00 
0.00-10.00 
 
2.92 
3.20 
2.84 
 
5.00 
5.00 
4.00 
 
[(t=-1.099; p=.275)(U=159.00; 
p=.293)] 
(U=116.00; p=.039) 
(U=159.00; p=.240) CT/TT 
Preoperative Pain 
PACU Pain 15 
PACU Pain 45 
 
6.00 
2.83 
7.33 
 
7.50 
0.00 
8.50 
 
0.00-10.00 
0.00-10.00 
0.00-10.00 
 
4.05 
4.49 
3.78 
 
8.00 
7.8 
4.80 
 
*SD=Standard deviation; IQR=Interquartile range 
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4.5 DISTRIBUTION OF OPIOID USE BY A118G AND C17T GENOTYPES 
The fourth specific aim was to examine the differences in the distribution of opioid use during 
OR time and the first 45 minutes in the PACU by genotype. Table 6 describes opioid use during 
OR time and the first 45 minutes in the PACU for each genotype. Although the PACU opioid use 
for CC genotype (M=6.45; SD=5.63) and the variant CT/TT (M=10.43; SD=9.22) genotypes 
appeared quite different based on descriptive statistics, there were no significant differences 
found in opioid use during OR time and the first 45 minutes in the PACU between the wild-type 
and variant genotypes for A118G or C17T. 
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Table 6. Descriptive and Comparative Statistics for Opioid use by A118G and C17T Genotypes 
Genotypes/Outcomes Mean 
 
Median  
 
Min-Max 
 
SD 
 
IQR 
 
Test Stat 
Mann-Whitney U-test 
AA 
OR Opioid use 
OR Opioid use by wt 
PACU Opioid use  
PACU Opioid use by wt 
 
34.538  mg 
0.398 mg/kg 
6.433  mg 
0.079 mg/kg 
 
32.000 mg 
0.361 mg/kg 
6.000 mg 
0.079 mg/kg 
 
8.000-108.000 mg 
0.000-1.460 mg/kg 
0.000-26.660 mg 
0.000-0.275 mg/kg 
 
19.216 mg 
0.234 mg/kg 
5.970 mg 
0.074 mg/kg 
 
18.500 mg 
0.249 mg/kg 
10.000 mg 
0.125 mg/kg 
 
(U=569.00; p=.586) 
(U=561.00; p=.596) 
(U=499.00; p=.362) 
(U=475.50; p=.238) 
 
 
AG/GG 
OR Opioid use 
OR Opioid use by wt 
PACU Opioid use  
PACU Opioid use by wt  
 
36.439 mg 
0.463 mg/kg 
7.745 mg 
0.103 mg/kg 
 
35.000 mg 
0.360 mg/kg 
7.333 mg 
0.094 mg/kg 
 
5.000-85.000 mg 
0.074-1.350 mg/kg 
0.000-18.600 mg 
0.000-0.255 mg/kg 
 
19.719 mg 
0.295 mg/kg 
6.069 mg 
0.082 mg/kg 
 
26.000 mg 
0.423 mg/kg 
10.700 mg 
0.161 mg/kg 
CC 
OR Opioid use 
OR Opioid use by wt 
PACU Opioid use  
PACU Opioid use by wt  
 
35.119 mg 
0.415 mg/kg 
6.446 mg 
0.082 mg/kg 
 
33.000 mg 
0.360 mg/kg 
6.000 mg 
0.082 mg/kg 
 
5.000-108.000 mg 
0.073-1.460 mg/kg 
0.000-20.000 mg 
0.000-0.267 mg/kg 
 
19.343 mg 
0.252 mg/kg 
5.629 mg 
0.075 mg/kg 
 
16.750 mg 
0.241 mg/kg 
10.000 mg 
0.134 mg/kg 
 
(U=227.00; p=.989) 
(U=210.00; p=.796) 
(U=160.00; p=.262) 
(U=165.50; p=.308) 
 
 
CT/TT 
OR Opioid use 
OR Opioid use by wt 
PACU Opioid use  
PACU Opioid use by wt 
 
33.388 mg 
0.393 mg/kg 
10.431 mg 
0.120 mg/kg 
 
31.500 mg 
0.450 mg/kg 
10.300 mg 
0.115 mg/kg 
 
10.000-63.330 mg 
0.000-0.653 mg/kg 
0.000-26.660 mg 
0.000-0.275 mg/kg 
 
19.375 mg 
0.241 mg/kg 
9.223 mg 
0.096 mg/kg 
 
32.83 mg 
0.380 mg/kg 
13.168 mg 
0.159 mg/kg 
*SD=Standard deviation; IQR=Interquartile range 
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5.0  CHAPTER 5: DISCUSSION 
A polymorphism is considered a minor allele found at least in 1% of the population (NCI n.d.). 
Therefore the primary importance of this study was to explore the allele and genotype 
frequencies and analyzing the genotypic frequencies for the SNPs, A118G and C17T, found on 
the OPRM1 gene.  These frequencies were then compared to those found in other studies in 
order to infer the genotypic variation in the overall population.  It is known that the A118G and 
C17T SNPs have been known to vary between races, and so another focus of this study was to 
compare the genotypic frequencies between races/ethnicities. This analysis was performed in 
order to provide greater insight in the complex nature of pain that often varies with factors such 
as culture and personality.  Subsequent aims such as analyzing opioid use and pain score by 
genotype provided further insight into the implication of genetics on pain and its response. 
5.1 VARIATION OF A118G AND C17T GENOTYPES WITHIN SAMPLE 
 
 Many of the polymorphisms of interest in the OPRM1 gene occur within the exon coding region 
as these changes lead to amino acid substitutions and hence may affect protein function.  The A 
to G SNP at position 118 which changes asparagine to aspartic acid has been documented to 
result in a higher affinity for endogenous opioids, yet either a lower or no difference in binding 
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of exogenous opioids (Bond et al 1998). Therefore understanding the distribution of genotypes 
and alleles in this sample would allow us to better make connections to other outcomes such as 
opioid use and pain score.  For the overall sample consisting of 83 subjects the allelic frequency 
of the variant G allele was 12.65% .  This is similar to the frequencies found by National Center 
for Biotechnological Information (NCBI), which reports 13.0% (NCBI-rs17999711 1998).  
Similarly, this population consisted of 72 subjects of Caucasian and African-American 
race/ethnicity.  According to LaForge et al (2000) who conducted a meta-analysis, the G allele 
was found to have a frequency ranging from 9% to 32%. Ones study’s results from NCBI’s 
database for A118G genotypes reported 71.3% with AA, 23% with AG, and 5.7% with GG 
(NCBI-rs17999711 1998).  These genotypic frequencies correspond to the frequencies found in 
this study, 75.9% for AA, 22.9% for AG, and 1.2% (1 subject) for GG.   
The C to T SNP at position 17 has not been documented to result in a specific 
mechanistic change such as that seen in A118G, but Bond et al (1998) did find a higher 
frequency of the variant T allele amongst those who were opioid-dependent.  This study did not 
evaluate substance abuse such as opioid-dependence, but understanding the frequency of the 
variant allele and genotypes within the sample may provide further insight into the prevalence 
C17T being linked to substance abuse.  The allelic frequency for this sample was 4% for the T 
allele. These results were compared to those found in NCBI database for the T allele, 4.2%-7% 
(NCBI-rs17999712 1998).   LaForge et al (2000) reported a range of 1 to 16% for the T allele.  
The allelic frequencies for this study reflect the genotypic frequencies reported in the literature 
with 92.8% having CC, 6.0% having CT, and 1.2% (1 subject) having TT.  Similarly NCBI’s 
genotype frequencies were as follows: 89.0% for CC, 7.0% for CT, and 4.0% for TT (NCBI-
rs17999712 1998).   However because C17T was not in HWE further these analyses could not be 
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projected to the population.  These variations from HWE in genotypic frequency may result from 
the differences in sample species, size, geographic location, and also the methods used to detect 
the genotypes.   
5.2 VARIATION OF A118G AND C17T GENOTYPES BY RACE/ETHNICITY 
 
The literature has reported that the single nucleotide polymorphisms found on the OPRM1 
receptor at positions A118G and C17T vary between race/ethnicity.  In the analyses we 
examined the Caucasian and African-American races/ethnicities as they were the 
races/ethnicities that composed the majority of the sample.  In analyzing the frequency of the G 
allele, this study found it was present in 12.5% of Caucasians and 10% of African-Americans. 
This is comparable to the NCBI database, which reports the G allele in frequencies between 
11.9%-16.7% for the Europeans samples and 0.8%-4.2% for African samples (NCBI-rs17999711 
1998).   The genotype frequency for Caucasians in this study was 76.6% for AA, 21.9% for AG, 
and 1.2% for GG.  For African-Americans 80% were found to have AA, whereas 20% had AG 
and none were found to have the subsequent variant genotype, GG.  Again this is comparable to 
the NCBI database as 70%-79.2% of Caucasians/Europeans have the AA genotype, 16.7%-29% 
have the AG gentoype, and 1.1%-4.2% had the GG genotype (NCBI-rs17999711 1998).    For 
Africans-Americans the database reports 91.9%-100% as having the AA genotype, 0% to 4.3% 
having the AG gentoype, and none of their African samples had the GG genotype (NCBI-
rs17999711 1998).   Analyses of these data did not find any significant differences in these 
distributions between race/ethnicity.  As Gelernter et al (1999) illustrates the G allele, at 49% 
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within the Japanese sample, is found predominately in Asian populations. Therefore the data 
may have shown significance if Asians composed a higher proportion of the sample.  
The variant allele, T, for the C17T SNP has been reported to have a higher frequency 
within the African/African-American population.  The results verified this as the T allele was 
found in 30% of the African-American sample.  Similarly the genotypic distribution for African-
Americans was proportionally more diverse than that found for Caucasians as 50% of African-
Americans had the CC genotype, 40% had the CT genotype, and 10% had the TT genotype.  
Conversely the T allele was found in 1% of Caucasians and 98% had CC genotype, 2% had CT 
genotype, and none exhibited the variant TT genotype.  Based on the Fisher exact test African-
Americans were found to be significantly more likely to exhibit either the CT or TT variant 
genotypes (p<.001).  This result is comparable to LaForge et al (2000) who found the T allele 
and CT/TT genotypes highest within African-Americans and Bond et al who found the CT/TT 
genotypes significantly higher within those opioid-dependent African-Americans. This finding 
may show a genetic link to substance abuse, which is prevalent amongst the African-American 
population.  As the findings of 30% for the T allele is higher than that found in most studies, 
further sampling of the African-American population within this geographic area might reveal 
significant correlations between the variant T allele and CT/TT genotypes and addiction. 
5.3 PAIN SCORES BY GENOTYPES 
In order to analyze whether the SNPs in A118G and C17T altered pain perception, pain scores 
were analyzed between the wild-type and variant genotypes.  Using the verbal pain scale, VPS, 
for preoperative and PACU pain within 15 and 45 minutes, this study did not find a significant 
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difference in self reported pain levels between the wild-type genotype for A118G and the variant 
genotypes, AG or GG.  This is in contrast to other studies such as Fillingim et al (2005) that have 
measured pressure pain sensitivity and found a significantly higher pain threshold for those with 
the variant allele, G.  Perhaps adjusting the method of data collection for pain such as correlating 
the VPS with neuronal imaging such as that used by Coghill et al (2003) will result in more 
significant and robust quantitative results.  In analyzing the difference in pain responses between 
the C17T genotypes, a significant difference of was found for lower pain scores amongst those 
with the CT and TT genotypes (p=.039). Three out of the six subjects with the CT/TT genotype 
reported a rating of 0/10 for pain within 15 minutes after admittance to the PACU.  This is in 
comparison to the entire sample that reported a mean PACU pain score of 6.53 within 15 
minutes.  This finding of significantly lower pain responses after orthopedic trauma surgery for 
subjects with the variant CT/TT genotypes has not been documented in other studies.  This 
finding may show that the T allele confers added resistance against immediate post-operative 
pain.   
5.4 OPIOID USE BY GENOTYPES 
It was believed that analyzing opioid use by genotype would offer insight into the differences 
between the wild-type and variant genotypes for A118G and C17T in binding exogenous 
opioids. As the variant allele G increases the affinity of binding endogenous opioids, many 
studies have examined the effects of this allele and variant genotypes, AG/GG, on binding of 
exogenous opioids. The study analyzed OR opioid use and PACU opioid use within the first 45 
minutes, taking into account body weight in determining opioid distribution within the body.   
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The results for A118G did not show a significant difference in opioid use between the wild-type 
AA and variant AG genotype.  Previous studies, however, have found a correlation between the 
G allele and opioid use.  Reyes-Gibby et al (2007) found that those subjects with the GG 
genotype had a significantly higher need for opioids in relation to cancer pain than those with the 
AA or AG genotypes. Lotsch et al (2006) also found that the G allele had a decreased affinity for 
morphine and its metabolite, morphine-6-glucuronide. Bond et al (1998), however, did not find a 
difference between opioid use in those with or without the 
A118G SNP.  These discrepancies are highlighted by Reyes-Gibby et al (2007), who also 
showed that the GG genotype had the lowest pain scores indicating that there may not be a 
distinct correlation between pain and opioid use. 
Similarly, the results for C17T did not show significance in opioid use between 
genotypes.  There, however, was a large difference in PACU opioid use based upon descriptive 
statistics between CC and CT/TT genotypes with the CT/TT using an average of 10.43mg of 
morphine equivalents as compared to 6.45mg for the CC genotype (p=.262). These findings do 
not support the literature which has found higher proportions of opioid use amongst those with 
the CT/TT genotypes and also linked the variant genotypes to opioid-dependence and other 
forms of substance abuse.  
5.5 SUMMARY 
The most crucial finding of this study were that the C17T variant genotypes, CT and TT, were 
found significantly higher within the African-American sample as compared to the Caucasian 
sample. This finding supports the literature that SNPs in the OPRM1 gene vary between 
race/ethnicity.  The most pertinent question then is what are the effects of variant OPRM1 
genotypes for A118G and C17T on pain and opioid use?  This study did not add conclusive 
evidence that pain and opioid use have associations with variations in the A118G and C17T 
genotype.  Even though we did find that PACU pain scores within 15 minutes were significantly 
lower amongst those with the CT and TT genotypes, this finding was not consistent with the 
other assessment points of pain, which were higher for the CT/TT group preoperatively and in 
the PACU within 45 minutes.  This study also did not find a significant amount of opioid use 
between wild-type and variants genotypes in both A118G and C17T.  This is somewhat 
surprising as the literature has found those with G allele for A118G require increased amounts of 
exogenous opioids as the binding affinity is for the mutant mu receptor is decreased.  This 
decreased binding affinity is perhaps explained by the amino acid substitution of asparagine for 
aspartic acid.  As aspartic acid is a charged amino acid, it may destabilize interactions between 
the binding site on the mu opioid receptor and morphine. The literature has not found any 
conclusive evidence that binding affinity is changed with the C17T substitution and that may be 
validated by the change in amino acids (alanine for valine) resulting in similar hydrophobic 
interactions (Matthews et al 2003).  
Overall the findings were somewhat contradictory to those found in the literature as we 
found a nonsignificant need for opioids amongst those with the C17T variant allele, T, for the 
PACU period.  Synthesizing these results it may be concluded that those with the C17T variant 
genotypes, CT and TT, may have OPRM1 receptors than bind exogenous opioids with a stronger 
affinity, yet for shorter time frame.  This decrease in binding time may be a result of difference 
in metabolism of morphine’s active metabolite, morphine-6-glucuronide.  Rakvag et al (2005) 
and Reyes-Gibby et al (2007) both found that morphine consumption is influenced by the 
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enzymatic activity of catechol-O-methyltransferase, COMT.  Looking at COMT within cancer 
patients Rakvag et al (2005) found that those with the Val/Val genotype required more amounts 
of morphine than those with the Met/Met genotype. Reyes-Gibby et al (2007), however, found a 
correlation between COMT and OPRM1 for the A118G genotypes. They also found that those 
with the Met/Met genotype for COMT and AA for A118G required the lowest amounts of 
opioids in comparison to those without both of these genotypes (Reyes-Gibby 2007). This 
therefore suggest that there may be an association between dissimilar genes and pain modulation 
and further research between C17T and other genes such COMT may show this correlation.  The 
needed increase in opioids within the C17T sample with the variant genotypes may also suggest 
that there is an increased rate of tolerance of morphine and this may be linked to the increased 
opioid dependence seen in those with the CT and TT genotypes.  Of course cultural components 
may also add confounding variables that distort the genetic explanations. 
5.6 LIMITATIONS 
The C17T sample was not found to be within HWE.  This may be a result of sample 
demographics.  Those with orthopedic trauma injuries usually exhibit a higher level of risk 
taking and this may have a genetic component that correlates pain perception with the propensity 
for risk-taking behavior.  In fact a study by Bart et al (2005) researched the correlation between 
OPRM1 and other genes related to risk-taking behavior. These have primarily been performed in 
the A118G genotype and further exploration between risk-taking genes and the C17T genotype 
may show significant correlations. 
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The results of this study were affected by numerous factors within the methods plan.  
Small sample size was most likely due to recruitment occurring at one site and also within a 
specific population of isolated extremity fractures with few co-morbidities and no history of 
opioid use.  Orthopedic trauma injuries are common amongst those with risk taking behavior and 
hence this population may have a high incidence of substance abuse.  Expanding the sample size 
to other sites and recruiting those subjects with prior opioid use and co-morbidities may expand 
the number of subjects.  These subjects, however, would receive their own separate categories 
for analyses as these factors may alter the pharmacodynamics of opioids.  The expansion beyond 
the current geographic location would also add racial/ethnic diversity to the sample. 
Isolating race/ethnicity was another limitation of this study.  Subjects were recruited by 
racial categories instead of ethnicity, and this excludes some diversity that may found amongst 
the distribution of alleles and genotypes.  For example Gelernter et al (1999) found that 17% of 
Ethiopians exhibited the G allele as compared to 3% of African-Americans. In this study the two 
groups would have been collapsed into one.  Separating subjects by ethnicity may produce more 
relevant results. 
A further limitation was the way in which some of the results were collected such as pain 
scores and opioid use.  Both had compromises in accuracy as they were taken from both the 
medical record and patient report.  These two methods do not always agree as there may be 
discrepancies between the patient report and the healthcare provider recording the data.  An 
increased number of recruiters would help ensure that most of the information was taken directly 
from patient report or from the recent medical record and any discrepancies could be clarified 
with the patient and healthcare provider.   
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5.7 CONCLUSIONS 
This study evaluated the frequency and effect of the variant genotypes of A118G and C17T for 
OPRM1.  The findings of this study showed that the genetic variability in the C17T SNP is found 
most frequently in the African-American group.  They are more likely to have the variant, T, 
allele and therefore the variant CT and TT genotypes.  Those with CT/TT are also more likely to 
have a reduced amount of pain within the immediate PACU period, but show a need for 
increased opioid use.  These findings of greater opioid use amongst those with the CT/TT 
genotype which is commonly found in African-Americans signifies that a genetic component 
may be affecting opioid dependence and other forms of substance abuse.   
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